Is AYTU or CING more profitable?

Cingulate has a net margin of 0.00% compared to Aytu BioPharma's net margin of -24.76%. Aytu BioPharma's return on equity of -63.03% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Aytu BioPharma -24.76% -63.03% -12.74% Cingulate N/A -238.40% -128.67%

Does the media favor AYTU or CING?

In the previous week, Aytu BioPharma had 9 more articles in the media than Cingulate. MarketBeat recorded 11 mentions for Aytu BioPharma and 2 mentions for Cingulate. Cingulate's average media sentiment score of 0.39 beat Aytu BioPharma's score of 0.29 indicating that Cingulate is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aytu BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cingulate 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AYTU or TENX?

In the previous week, Aytu BioPharma had 8 more articles in the media than Tenax Therapeutics. MarketBeat recorded 11 mentions for Aytu BioPharma and 3 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.61 beat Aytu BioPharma's score of 0.29 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aytu BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tenax Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Aytu BioPharma (AYTU) Competitors

$2.28 +0.05 (+2.24%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.22 -0.06 (-2.59%)

As of 08:00 AM Eastern

Compare

AYTU vs. ALDX, FBIO, VRCA, CING, and TENX

Should you buy Aytu BioPharma stock or one of its competitors? Aytu BioPharma's main competitors and comparable companies include Aldeyra Therapeutics (ALDX), Fortress Biotech (FBIO), Verrica Pharmaceuticals (VRCA), Cingulate (CING), and Tenax Therapeutics (TENX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aytu BioPharma compare to Aldeyra Therapeutics?

Aytu BioPharma (NASDAQ:AYTU) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aldeyra Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -24.76%. Aldeyra Therapeutics' return on equity of -53.14% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-24.76%	-63.03%	-12.74%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

Aytu BioPharma has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$57.57M	0.42	-$13.56M	-$1.66	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

In the previous week, Aytu BioPharma had 11 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 11 mentions for Aytu BioPharma and 0 mentions for Aldeyra Therapeutics. Aytu BioPharma's average media sentiment score of 0.29 beat Aldeyra Therapeutics' score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
Aldeyra Therapeutics	Neutral

Aytu BioPharma has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Aytu BioPharma presently has a consensus target price of $10.75, indicating a potential upside of 371.49%. Aldeyra Therapeutics has a consensus target price of $5.50, indicating a potential upside of 307.41%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Aytu BioPharma is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aytu BioPharma beats Aldeyra Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Aytu BioPharma compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Fortress Biotech currently has a consensus target price of $17.00, indicating a potential upside of 626.50%. Aytu BioPharma has a consensus target price of $10.75, indicating a potential upside of 371.49%. Given Fortress Biotech's higher possible upside, equities research analysts plainly believe Fortress Biotech is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Fortress Biotech has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Fortress Biotech has a net margin of 163.32% compared to Aytu BioPharma's net margin of -24.76%. Fortress Biotech's return on equity of 83.47% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Aytu BioPharma	-24.76%	-63.03%	-12.74%

Fortress Biotech has higher revenue and earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.23	$6.82M	$2.64	0.89
Aytu BioPharma	$57.57M	0.42	-$13.56M	-$1.66	N/A

In the previous week, Aytu BioPharma had 11 more articles in the media than Fortress Biotech. MarketBeat recorded 11 mentions for Aytu BioPharma and 0 mentions for Fortress Biotech. Aytu BioPharma's average media sentiment score of 0.29 beat Fortress Biotech's score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Fortress Biotech	Neutral
Aytu BioPharma	Neutral

Summary

Fortress Biotech beats Aytu BioPharma on 12 of the 16 factors compared between the two stocks.

How does Aytu BioPharma compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Verrica Pharmaceuticals currently has a consensus target price of $12.67, suggesting a potential upside of 174.17%. Aytu BioPharma has a consensus target price of $10.75, suggesting a potential upside of 371.49%. Given Aytu BioPharma's higher probable upside, analysts clearly believe Aytu BioPharma is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aytu BioPharma has a net margin of -24.76% compared to Verrica Pharmaceuticals' net margin of -102.84%. Aytu BioPharma's return on equity of -63.03% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Aytu BioPharma	-24.76%	-63.03%	-12.74%

In the previous week, Aytu BioPharma had 11 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 11 mentions for Aytu BioPharma and 0 mentions for Verrica Pharmaceuticals. Aytu BioPharma's average media sentiment score of 0.29 beat Verrica Pharmaceuticals' score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Neutral
Aytu BioPharma	Neutral

Aytu BioPharma has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$30.32M	2.62	-$17.89M	-$1.67	N/A
Aytu BioPharma	$57.57M	0.42	-$13.56M	-$1.66	N/A

Summary

Aytu BioPharma beats Verrica Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Aytu BioPharma compare to Cingulate?

Aytu BioPharma (NASDAQ:AYTU) and Cingulate (NASDAQ:CING) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Aytu BioPharma has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$57.57M	0.42	-$13.56M	-$1.66	N/A
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A

Aytu BioPharma has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.88, meaning that its stock price is 188% less volatile than the broader market.

Aytu BioPharma currently has a consensus price target of $10.75, suggesting a potential upside of 371.49%. Cingulate has a consensus price target of $27.00, suggesting a potential upside of 442.17%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cingulate has a net margin of 0.00% compared to Aytu BioPharma's net margin of -24.76%. Aytu BioPharma's return on equity of -63.03% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-24.76%	-63.03%	-12.74%
Cingulate	N/A	-238.40%	-128.67%

In the previous week, Aytu BioPharma had 9 more articles in the media than Cingulate. MarketBeat recorded 11 mentions for Aytu BioPharma and 2 mentions for Cingulate. Cingulate's average media sentiment score of 0.39 beat Aytu BioPharma's score of 0.29 indicating that Cingulate is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aytu BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cingulate	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by company insiders. Comparatively, 5.3% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Aytu BioPharma beats Cingulate on 8 of the 14 factors compared between the two stocks.

How does Aytu BioPharma compare to Tenax Therapeutics?

Aytu BioPharma (NASDAQ:AYTU) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Aytu BioPharma has higher revenue and earnings than Tenax Therapeutics. Aytu BioPharma is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$57.57M	0.42	-$13.56M	-$1.66	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Aytu BioPharma has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Aytu BioPharma had 8 more articles in the media than Tenax Therapeutics. MarketBeat recorded 11 mentions for Aytu BioPharma and 3 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.61 beat Aytu BioPharma's score of 0.29 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aytu BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenax Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Tenax Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -24.76%. Tenax Therapeutics' return on equity of -61.54% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-24.76%	-63.03%	-12.74%
Tenax Therapeutics	N/A	-61.54%	-57.42%

Aytu BioPharma currently has a consensus price target of $10.75, suggesting a potential upside of 371.49%. Tenax Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 636.84%. Given Tenax Therapeutics' higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Tenax Therapeutics beats Aytu BioPharma on 9 of the 14 factors compared between the two stocks.

Get Aytu BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AYTU vs. The Competition

Export

Metric	Aytu BioPharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.93M	$12.61B	$7.31B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-1.37	792.28	274.10	25.70
Price / Sales	0.42	857.09	672.61	90.85
Price / Cash	5.94	88.64	77.80	52.76
Price / Book	1.08	10.57	10.48	6.32
Net Income	-$13.56M	$2.81B	$3.49B	$359.73M
7 Day Performance	14.00%	-0.17%	-0.68%	0.17%
1 Month Performance	-1.30%	-1.39%	-3.18%	-3.27%
1 Year Performance	10.68%	2.83%	15.13%	5.58%

Aytu BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AYTU Aytu BioPharma	2.1132 of 5 stars	$2.28 +2.2%	$10.75 +371.5%	-9.2%	$23.93M	$57.57M	N/A	83	Trending News Earnings Report Analyst Upgrade Gap Up High Trading Volume
ALDX Aldeyra Therapeutics	1.9181 of 5 stars	$1.40 +3.3%	$5.50 +294.3%	-73.6%	$81.44M	N/A	N/A	6
FBIO Fortress Biotech	1.8942 of 5 stars	$2.45 +1.7%	$17.00 +593.9%	-35.9%	$80.38M	$63.26M	0.93	78
VRCA Verrica Pharmaceuticals	4.0243 of 5 stars	$4.72 +5.1%	$12.67 +168.4%	+7.2%	$77.13M	$35.58M	N/A	76
CING Cingulate	2.6101 of 5 stars	$5.14 -1.7%	$27.00 +425.3%	+36.4%	$76.05M	N/A	N/A	14

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AYTU) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aytu BioPharma (AYTU) Competitors

AYTU vs. ALDX, FBIO, VRCA, CING, and TENX

How does Aytu BioPharma compare to Aldeyra Therapeutics?

Summary

How does Aytu BioPharma compare to Fortress Biotech?

Summary

How does Aytu BioPharma compare to Verrica Pharmaceuticals?

Summary

How does Aytu BioPharma compare to Cingulate?

Summary

How does Aytu BioPharma compare to Tenax Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aytu BioPharma (AYTU) Competitors

AYTU vs. ALDX, FBIO, VRCA, CING, and TENX

How does Aytu BioPharma compare to Aldeyra Therapeutics?

Do insiders & institutionals believe in AYTU or ALDX?

Is AYTU or ALDX more profitable?

Which has better valuation and earnings, AYTU or ALDX?

Does the media refer more to AYTU or ALDX?

Which has more volatility and risk, AYTU or ALDX?

Do analysts rate AYTU or ALDX?

Summary

How does Aytu BioPharma compare to Fortress Biotech?

Do analysts prefer FBIO or AYTU?

Which has more volatility & risk, FBIO or AYTU?

Do insiders & institutionals believe in FBIO or AYTU?

Is FBIO or AYTU more profitable?

Which has stronger earnings & valuation, FBIO or AYTU?

Does the media refer more to FBIO or AYTU?

Summary

How does Aytu BioPharma compare to Verrica Pharmaceuticals?

Do analysts rate VRCA or AYTU?

Which has more volatility & risk, VRCA or AYTU?

Do insiders & institutionals have more ownership in VRCA or AYTU?

Is VRCA or AYTU more profitable?

Does the media refer more to VRCA or AYTU?

Which has preferable earnings & valuation, VRCA or AYTU?

Summary

How does Aytu BioPharma compare to Cingulate?

Which has stronger valuation & earnings, AYTU or CING?

Which has more risk & volatility, AYTU or CING?

Do analysts rate AYTU or CING?

Is AYTU or CING more profitable?

Does the media favor AYTU or CING?

Do institutionals and insiders hold more shares of AYTU or CING?

Summary

How does Aytu BioPharma compare to Tenax Therapeutics?

Which has higher valuation & earnings, AYTU or TENX?

Which has more volatility & risk, AYTU or TENX?

Do institutionals & insiders have more ownership in AYTU or TENX?

Does the media favor AYTU or TENX?

Is AYTU or TENX more profitable?

Do analysts prefer AYTU or TENX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools